Rhythm Pharmaceuticals (RYTM) Return on Capital Employed (2017 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Return on Capital Employed of 55.12% for Q1 2026, up 705.0% year-over-year from 6.85% in Q1 2025, and down 11.27% quarter-over-quarter from 49.54% in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Return on Capital Employed (2017 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Return on Capital Employed for 10 consecutive years, with 55.12% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 705.0% year-over-year to 55.12%; the TTM figure through Mar 2026 stood at 55.12% (up 705.0% YoY), while the FY2025 annual figure was 58.14%, up 4936.0% from the prior year.
- Return on Capital Employed declined to 55.12% in Q1 2026 per RYTM's latest filing, from 49.54% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 49.54% in Q4 2025 and bottomed at 112.49% in Q1 2024.
- Historically, Return on Capital Employed has averaged 71.87% across 5 years, with a median of 64.08% in 2023.
- Annual changes were most pronounced in 2024 — Return on Capital Employed plunged 5621 bps — and 2025, when it surged 5164 bps.
- Rhythm Pharmaceuticals' Return on Capital Employed stood at 51.74% in 2022, then decreased by 24 bps to 63.95% in 2023, then slumped by 58 bps to 101.18% in 2024, then soared by 51 bps to 49.54% in 2025, then slipped by 11 bps to 55.12% in 2026.
- Business Quant data shows RYTM's Return on Capital Employed at 55.12% in Q1 2026, 49.54% in Q4 2025, and 55.5% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | -63.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -63.45% |
| Mar 31, 2026 | -55.12% |
| Dec 31, 2025 | -49.54% |
| Sep 30, 2025 | -55.50% |
| Jun 30, 2025 | -70.90% |
| Mar 31, 2025 | -62.17% |
| Dec 31, 2024 | -101.18% |
| Sep 30, 2024 | -96.51% |
| Jun 30, 2024 | -100.02% |
| Mar 31, 2024 | -112.49% |
| Dec 31, 2023 | -63.95% |
| Sep 30, 2023 | -65.69% |
| Jun 30, 2023 | -64.08% |
| Mar 31, 2023 | -56.28% |
| Dec 31, 2022 | -51.74% |
| Sep 30, 2022 | -62.57% |
| Jun 30, 2022 | -81.55% |
| Mar 31, 2022 | -72.47% |
| Dec 31, 2021 | -56.83% |
| Sep 30, 2021 | -44.21% |